Biomed

Executive Summary

Biomed Industries, Inc. is a private biopharmaceutical company advancing novel small molecule therapies for central nervous system and metabolic disorders. With a Phase 3 clinical program, Biomed targets high-unmet-need indications including ALS, Alzheimer's disease, Huntington's disease, major depressive disorder, and metabolic conditions like diabetes and MASH. Founded in 1987 and headquartered in Westminster, Colorado, the company leverages decades of drug development expertise. The advanced stage of its lead asset suggests potential near-term value inflection, though the private status limits visibility on financing and partnership activities.

Upcoming Catalysts (preview)

• H2 2026Phase 3 topline data readout for lead neuroscience candidate60% success
• Q4 2026Initiation of Phase 3 trial in metabolic disease (MASH or diabetes)50% success
• TBDStrategic partnership or licensing deal for pipeline asset40% success